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ABSTRACT 
Gliomas are the most common primary central nervous system (CNS) tumor and 
are associated with a particularly poor prognosis despite the advances of 
multimodality therapy.  Recent work demonstrating an association between 
gliomas and cytomegalovirus (CMV) infection has led us to postulate that 
modulation of key viral gene products presents an attractive opportunity to 
selectively deliver therapy to this refractory CNS tumor. We hypothesize that 
drugs capable of targeting epigenetic processes will provide antitumor activity 
while simultaneously inducing viral gene products that can subsequently be 
targeted by a variety of agents including nucleoside analogues.  Here we provide 
data demonstrating that drugs with histone deacetylase inhibitor (HDACi) activity 
facilitate glioblastoma cell cycle arrest and apoptosis in vitro.  The glioma cell 
lines, Gli3605 and U251, and the neuroblastoma lines, NB11 and NB11 CMV 
were used in experiments to test our hypothesis.  All lines treated with the HDACi 
depsipeptide or HDACi 42 underwent induction of programmed cell death in a 
dose-dependent fashion. However, the CMV-infected NB11 cell line 
demonstrated increased resistance to HDACi-mediated apoptosis.  Treatment of 
the NB11 CMV cell line with doses of depsipeptide and HDACi 42, previously 
shown to inhibit histone deacetylase activity, resulted in the induction of the CMV 
protein kinase UL97 in a dose-dependent fashion.  Addition of the nucleoside 
analogue ganciclovir (GCV) to HDACi-treated cells resulted in enhanced cell 
death that selectively occurred in NB11 CMV cells but not the parental line NB11 
suggesting a CMV-specific effect.  These data support consideration of combined 
use of histone deacetylase inhibitors and antiviral compounds in 
cytomegalovirus-associated malignant brain tumors. Studies are in progress to 
further characterize (i) mechanism(s) leading to enhanced HDACi-mediated 
UL97 expression, (ii) whether CMV-infected glioblastoma cell lines demonstrate 
similar findings and (iii) the effect of this combination treatment strategy in an in 
vivo model of PCNS-glioblastoma.   
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INTRODUCTION 
Central nervous system tumors.  In the United States alone, more than 
200,000 people are diagnosed with primary or metastatic central nervous system 
tumors annually.  Primary brain tumors encompass approximately 40,000 of 
these cases (1) and are the leading cause of solid tumor cancer death in children 
under the age of 20, the second leading cause in males ages 20-29, and the fifth 
leading cause in females ages 20-39 (2, 3).  The projected five- and ten-year 
relative survival rates for malignant brain tumors are 28% and 24% respectively. 
However, there is a large variation in survival estimates among different types of 
brain tumors.  Five-year survival rates exceed 85% for pilocytic astrocytomas but 
are less than 5% for glioblastomas (1, 4).  Survival generally decreases with 
older age at diagnosis, and thus children and young adults have better survival 
for most histologies (1, 4).  At present, the standard treatments for brain tumors 
include surgery, radiation therapy, and chemotherapy. These may be used either 
individually or in combination.  The current dilemmas pertaining to these 
treatments are their toxicity, lack of effectiveness, and lack of precise targets 
which would allow for tumor-specific therapy. 
 Arising from the glial support cells in the CNS, gliomas comprise 77% of 
all malignant brain tumors (5).  High grade malignant gliomas are aggressive 
CNS tumors that are divided into anaplastic astrocytomas (AAs, grade III) and 
glioblastoma (glioblastoma multiforme, GBM, grade IV) which can be 
distinguished based on their histopathologic features.  Glioblastoma is the most 
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common type of glioma at 51.9% while astrocytomas represent 21.6% of all 
gliomas as a grade III cancer (1).  The clinical manifestations of AA or GBM 
depend upon the position and size of the lesion within the CNS.  High grade 
astrocytomas generate symptoms and signs by local brain invasion or 
compression and frequently present with increased intracranial pressure (ICP). 
Generalized symptoms such as headache and altered mental status are the 
result of increased ICP, which can be caused by mass effect obstructing 
cerebrospinal fluid outflow that frequently leads to hydrocephalus.  Augmented 
ICP may lead to the classic clinical triad of headache, nausea, and papilledema. 
The most common focal signs and symptoms of high-grade gliomas are seizures 
and hemiparesis, while those less common include hemianopia, aphasia, 
apraxia, and neglect syndromes (6).  
 Once a malignant astrocytoma is suspected by a patient’s symptoms and 
imaging, he/she often proceeds to surgical resection with an attempt at maximal 
preservation of neurological function.  Unfortunately, the highly invasive nature of 
malignant gliomas often leads to poorly defined surgical margins and a high rate 
of local recurrence despite adjuvant chemoradiation (8, 9).   Adjuvant focal 
involved RT has been shown to improve local control and survival after resection 
in at least two randomized trials and has become the standard of care (10, 11).  
Two meta-analyses showed that the benefit of procarbazine or carmustine to 
adjuvant RT is modest but significant compared to RT alone.  Despite these 
advances, prognosis is still poor (12, 13).  The average survival of patients with 
GBM is projected at 14 weeks with conservative therapy, 20 weeks with surgical 
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resection alone, 36 weeks with surgery plus radiation therapy, and 40 to 50 
weeks with the addition of chemotherapy (7).  It is therefore obvious that these 
treatments have only very limited effectiveness, and new approaches are 
needed.  
 
Cytomegalovirus and cancer. Human cytomegalovirus (HCMV), a B-
herpesvirus, is a major pathogen that is associated with a variety of diseases 
including encephalitis, neuroblastoma, glioblastoma (27), and colorectal cancer 
(14, 15).  This virus is trophic for a wide range of cellular phenotypes and 
ubiquitously infects 50–90% of the adult human population.  HCMV can be 
reinduced in individuals with chronic or acute inflammatory processes or 
immunosuppression.  HCMV gene products can disrupt multiple cellular 
pathways involved in mutagenesis, angiogenesis, apoptosis, cell cycle, cell 
invasion, and host immune response (16-26).  A large proportion (about 90%) of 
malignant gliomas are infected by HCMV, and multiple HCMV gene products are 
presented in these tumors (27).   
 Reactivation of an underlying persistent astrocytic or endothelial cell 
infection may lead to HCMV infection of glioma cells, or another possibility is de 
novo infection of glial cells that have accumulated cell cycle control defects. 
HCMV gene expression in a glial cell that does not lead to cell cycle arrest or 
apoptosis may perhaps promote clonal expansion without enacting a productive 
or cytopathic viral infection.  Contemporary studies have indicated that long-term 
passage of HCMV in malignant glioma cells can result in variant strains with 
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minimal cytopathic effect.  In latently infected glioma cells exposed to 
inflammatory stimuli or superinfected with other HCMV strains, HCMV can be 
reactivated (28, 29). 
HCMV has been shown to replicate in many cell types, including 
fibroblasts, neuronal cells, epithelial cells, endothelial cells, and macrophages 
(30).  Upon infection, the first genes to be transcribed by differential splicing of a 
primary transcript are the immediate early genes, which result in the two proteins 
IE1 p76 and IE2 p86 (31).  These immediate early proteins autoregulate the 
major immediate early promoter (MIEP) and activate several downstream cellular 
promoters (32-41).  The early genes of the virus are expressed as a result of 
immediate early expression, and these products are essential for DNA replication 
and lead to the expression of the late genes involved in virion assembly (44-46).  
It has also been shown that IE1 and IE2 promote viral replication by 
inhibiting histone deacetylation at HDAC3, and IE 86 interacts with the p53 
pathway by inhibiting Rb-mediated repression of transcription and consequently 
upregulating E2F (42-43).  HCMV-associated cancer is linked to uncontrolled cell 
replication caused by loss of p53 activity (48).    
 
Protein kinase UL97 and HDACi.  pUL97 is a well-characterized target of 
antiviral therapy, as specific activity of pUL97 is required to convert ganciclovir 
into its monophosphorylated derivative (49, 50).  Several reports have shown that 
UL97 acts as a ser/thr-specific protein kinase that can phosphorylate itself and 
other proteins (51, 52).  It has recently been revealed that UL97 is critical for 
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efficient HCMV replication and has no natural nucleoside kinase activity (53, 54).   
These recent discoveries provide insight as to why UL97 is an excellent target for 
antiviral therapy (55). Interestingly, drugs with histone deacetylase inhibitor 
(HDACi) activity promote infection of normally non-permissive, undifferentiated 
cells, resulting in HCMV permissiveness by inducing the activity of the MIEP (47).   
The acetylation status of core histones plays a pivotal role in regulating 
gene transcription through modulation of nucleosomal packaging of DNA (56-58).  
Nucleosomes are tightly compacted, which results in transcriptional silencing in 
the deacetylated form.  Alternatively, with histone acetylation, the nucleosomal 
structure becomes relaxed, leading to transcription.  There is a dynamic balance 
between these states with the activities of histone acetyltransferases (HATs) and 
histone deacetylases (HDACs) both of which are recruited to target genes 
(Figure 1).  Improper regulation of this epigenetic system has been shown to 
cause inappropriate gene silencing, a key event in the pathogenesis of many 
forms of cancer (59-60).   Because of this, it is highly likely that a class of drugs 
that inhibit histone deacetylase will promote CMV replication and, perhaps, 
derepress key promoters allowing for expression of viral proteins that can be 
targeted for tumor specific therapy.  
 
Overview of depsipeptide and HDACi 42.  Depsipeptide is a fermentation 
product from Chromobacterium violaceum first isolated by Fujisawa Company 
(61).  Depsipeptide has demonstrated potent cytotoxic activity against human 
tumor cell lines and in vivo efficacy against both human tumor xenografts and 
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murine tumors, such as the subcutaneously implanted LOX melanoma, MX-1 
mammary, NC1-H522 lung and UACC-62 melanoma (62).  This compound 
shows an apparent lack of cross-resistance with vincristine, 5-FU, mitomycin-C 
and cyclophosphamamide (62).  The compound can decrease expression of c-
myc oncogene by decreasing its mRNA expression in H-ras transfected NIH 3T3 
cells but has no effect on H-ras mRNA expression (63).  In vitro studies 
conducted by Fujisawa Pharmaceuticals Co. Ltd. demonstrate that depsipeptide 
has potent antiproliferative activity against 12 human cancer cells lines (IC50 
values ranged between .55 and 4.44 nM but are less potent against cultured 
animal cells such as human HNF fibroblasts (IC50>10000 ng/ml)) (62).  The in 
vitro potency of depsipeptide was confirmed in the NCI human tumor cell line 
drug screen (64).  
The in vivo antitumor efficacy of depsipeptide was evaluated in several 
murine tumor and human tumor xenograft models by Fujisawa Pharmaceuticals 
Co, Ltd. (62) as well as by the NCI (64).  The Southern Research Institute 
conducted studies in dogs which indicated that longer infusion times significantly 
diminish acute toxicity (64).  Intravenous administration of 1.0 or 2.0 mg/kg *20 or 
40 mg/m2) over 30 sec resulted in acute toxicity and death 2-8 days after drug 
administration in 5 of 14 dogs.  When the same dose was administered over a 
four minute period, increases in LDH and CPK were seen but no deaths 
occurred.  When the administration was prolonged to one hour infusion, the 
same doses led to minimal acute toxicity 
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HDACi 42 is a novel histone deacetylase inhibitor developed here at Ohio 
State University (Ching-Shih Chen Laboratory) which is 10,000-fold more potent 
than the parent molecule, phenylbutyrate.  Preliminary in vitro and in vivo studies 
have shown that it has potent antitumor activity in a variety of cancers (61).  
Experiments are currently underway to determine its potency in a variety of in 
vivo cancer models.  
 We hypothesize that the use of histone deacetylase inhibitors will result 
in activation of replication and derepression of key promoter elements.  This will 
allow for efficient expression of the UL97 protein in any CMV+ tumor cell, thus 
conferring sensitivity to the toxic effects of ganciclovir (GCV).  
 Thus far, the use of depsipeptide and HDACi 42 has been explored in 
glioblastoma lines.  Additionally, UL97 has been induced with these compounds 
in the cell line NB 11 CMV, a neuroblastoma line used as a positively infected 
cytomegalovirus model.  This induction has been shown to confer sensitivity to 
GCV and enhance HDACi-induced cell death.  The preclinical development of 
this strategy is therefore justified, and steps are currently being taken to create a 
Gli3605 cell line constitutively expressing luciferase for use in a primary brain 
tumor model.  Ultimately, we hope to move ahead into a clinical trial exploring the 
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MATERIALS AND METHODS  
Cell lines.  Gli3605 and U251 glioma tumor cells were obtained from the lab of 
Dr. E. Antonio Chiocca in the Department of Neurosurgery at Ohio State 
University. The NB11 and NB11 CMV neuroblastoma cell lines were obtained 
from Dr. James Waldman, Department of Pathology.  All cells were cultured in 
RPMI-1640 containing 5-10% Fetal Bovine Serum, 1% Penicillin/Streptomycin.  
NB11 and NB11 CMV lines were specifically obtained for use as a 50% 
permissively infected model of CMV+ cancer (65).   
Histone Deacetylase Inhibitors.  Depsipeptide was obtained from John Wright 
(NCI, CTEP) with permission of Fujisawa Inc.  The drug was used in 
concentrations of 0, 10, 50, 100, and 500 nM for experimental dose titrations and 
treatments of glioma and neuroblastoma cell lines.  HDACi 42 was provided by 
Dr. Ching-Shih Chen, Department of Internal Medicine, The Ohio State 
University, and used in concentrations of 0, 0.5, 1, 2, 3, 5, and 10 uM.  Dimethyl 
sulfoxide (DMSO) was employed as the vehicle control at a dilution of 1:1000 
from stock.  294uL was added per 3 mL.  Following a four hour incubation in drug 
or vehicle control (DMSO), cells were washed and placed into standard growth 
medium (or experimental conditions).   
Nucleoside analog.  Ganciclovir (GCV), an antiviral compound, was diluted to a 
concentration of 100 ug/mL from a 50 mg/mL stock.  It was then utilized in 
combination with either Depsipeptide or HDACi 42 in an experiment including the 
NB11 and NB11 CMV+ lines. The purpose of this drug pairing was to explore the 
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combinatorial effects of histone deacetylase inhibitors and antivirals on CMV-
infected cells. 
Flow cytometry.  Cells were analyzed for either cell cycle or apoptosis.  Since 
all cells used were adherent, a separate 6 or 12-well plate was used for each 
time point.  Media was pipetted from the plate and saved in collection tubes.  
Then, cells were washed with 1 mL phosphate buffered saline (PBS) per well, 
and the wash was also saved.  To remove the cells, 300 uL of Trypsin-EDTA was 
added, and the plates were incubated at 37oC for five minutes. Next, cells were 
removed by washing with 500 uL PBS and placed in the labeled tubes with the 
aforementioned media and PBS collections.  Samples were spun down in a 
centrifuge, and the supernatant was aspirated.  Then, the cells were 
resuspended in 2 mL PBS to wash, spun again, and the PBS was aspirated.  
Each sample was resupended in 300 uL of 1X Annexin binding buffer for an 
apoptosis assay.  Subsequently, 3 uL of Annexin V (FL1) were added, and the 
samples were incubated on ice for 15 minutes.  5 uL of Topro (FL 4) were added 
just prior to analysis by flow cytometry.  In the case of cell cycle analysis, 
samples were resuspended in 400 uL of PI (propidium iodide) buffer.  All 
samples were analyzed using Becton-Dickinson’s FACscalibur flow cytometer 
and CellQuest software. 
 
RNA Isolation.  Fibroblasts permissively infected with cytomegalovirus AD169 
were obtained from Dr. James Waldman, Department of Pathology, The Ohio 
State University.  At 72 hours post-infection, RNA was isolated from these cells 
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using TRIZOL Reagent.   According to the protocol provided by C6 DiagnosticsTM, 
the cells were lysed directly in the culture dish by adding 1 mL of TRIZOL 
Reagent per 10 cm2 of the dish, and the lysate was homogenized by passing it 
through a pipette several times.  Then, the samples were incubated at room 
temperature (RT) for 5 minutes, and 0.2 mL chloroform was added for each mL 
of TRIZOL originally added.  Tubes were shaken vigorously for 15 seconds, 
incubated at RT for 2-3 minutes, and centrifuged at 12,000 x g for 15 minutes at 
4oC.  The resulting aqueous phase was transferred to a new tube and 
precipitated by the addition of 0.5 mL isopropyl alcohol per 1 mL TRIZOL 
Reagent.  Subsequently, the samples were incubated at RT for 10 minutes and 
centrifuged at 12,000 x g for 10 minutes at 4oC.  The supernatant was withdrawn 
from the precipitate, and the resulting pellet was washed by adding 1 mL 75% 
ethanol for 1mL TRIZOL Reagent originally used.  The sample was vortexed to 
mix, and centrifuged at 7400 x g for 5 minutes at 4oC.  The RNA pellet was 
vacuumed and then air-dried for 20-30 minutes and resuspended by pipetting in 
20uL of RNase-free water and incubating at 55oC for 10 minutes.  Following 
isolation, the concentration of the RNA was determined using a UV 
spectrophotometer, and the presence of 18S and 28S ribosomal RNA species 
was evaluated by agarose gel electrophoresis.  All samples were stored at -80oC. 
 
Reverse Transcription and PCR.  A reverse transcription was performed using 
a kit purchased from InvitrogenTM, which included the MMLV-RT enzyme.  RT-
PCR was performed following manufacturer’s suggestions.  Briefly, 1.5 uL 
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random primers, 2 uL RNA (1.165 ug/uL), and 11.5 uL H2O were combined, 
placed on a PCR block at 70oC for 2 minutes, and then immediately placed on 
ice.  Subsequently a master mix containing 6.0 uL 5X Buffer, 3.0uL DTT (0.1 M), 
1.5 uL dNTP mixture (10 mM each), 1.5 uL MMLV-RT, and 1.0 uL H2O was 
added for a total volume of 30 uL.  The samples were placed on a PCR block for 
one cycle of 60 minutes at 42oC, 5 minutes at 94oC, and 4oC indefinitely.  The 
resulting cDNA was stored at -20oC. 
      The Polymerase Chain Reaction (PCR) was performed using the TaKaRa LA 
TaqTM kit from Takara Bio Inc. (Japan).  The primers used were 5’ (UP) EcoRI-
CCGGAATTCCATGTCCTCCGCACTTCGGTCTCG-3’ and 5’ (DN) Xho-
GGCCTCGAGTTACTCGGGGAACAGTTGGCGGCA-3’.  To achieve a final 
volume of 25 uL, 0.25 uL TaKaRa LA TaqTM enzyme, 12.5 uL 2X GC Buffer I, 4 
uL dNTP  mixture (2.5 mM each), 5.25 uL H2O, 1 uL each of forward and reverse 
primers, and 1uL cDNA were combined in a PCR tube.  The samples were 
placed on a PCR block for 30 cycles of 94oC/1 min., 94oC/30 sec., 60oC/30 sec., 
72oC/2 min., and 72oC/5 min. with a 4oC indefinite hold. 
 
Chemical transformation and sequencing.  The PCR products were mixed 
with Blue JuiceR and run on a 1% agarose gel with 2.5 uL Ethidium Bromide to 
determine the correct size of 2.1kB.  The products were then cut out of the gel 
and purified using Qiagen’sTM Gel Purification Protocol.  Next, the ligation was 
performed using the TOPO TA CloningR Kit provided by InvitrogenTM.  Combined 
in a tube were 4 uL PCR product, 1uL salt solution, and 1uL TOPOR vector, 
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which were incubated 5 minutes at RT.  One 50 uL vial of One ShotR Top 10 
competent E. Coli cells was thawed on ice for each ligation product, and 4 uL of 
this product was added to each vial of cells.  The vials were then incubated on 
ice for 30 minutes followed by a 30 second incubation at 42oC in a water bath.  
Subsequently, the vials were returned to ice, and 250 uL S.O.C. medium was 
added to each, after which they were shaken for one hour at 225 rpm and 37oC.  
LB agar plates containing 50ug/mL ampicillin were spread with 20-200 uL of 
reaction mixture and inverted at 37oC overnight. Colonies were picked, all of 
which grew out in liquid TB medium with ampicillin.   
 To determine correct vector-containing-insert size, 30 uL mini dye was 
added to each eppendorfR tube along with 30 uL phenochloroform and 50 uL 
transformed cells.  The tubes were then vortexed and spun at max speed for 2-3 
minutes.  The 1% agarose gel with 2.5uL EtBr was loaded with 50 uL of sample 
from the resulting aqueous layer.  Supercoil DNA marker was used as a marker.  
All samples were again selected, and mini preps were performed on the 800 uL 
of each colony according the Eppendorf Fast Plasmid MiniTM protocol.  The 
resulting DNA vector samples were then digested using 2 uL EcoRI, 2uL Buffer 
3, 11uL H2O, and 5 uL DNA at 37
oC for one hour.  The products were run on a 
gel to check for correct fragment and vector size, 2.1 kB and 3.9 kB, respectively.  
Clones with inserts of the correct size were sent for sequencing using M13 
forward and reverse primers with T3 and T7 polymerases, and all clones 
returned 97-98% homology to the UL97 CMV protein kinase, as determined 
using NCBI Nucleotide Blast software. 
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Immunohistochemical analysis.  In preparation for staining, three cytospins of 
both NB11 and NB 11 CMV+ were made.  Each slide held approximately 2000 
cells.  All six were fixed in ice-cold acetone.  According to the protocol supplied 
by Dr. James Waldman, cells were rehydrated in TBS (OSU Stores) and then 
placed in 1:5 horse serum (GibcoTM) diluted with TBS to block non-specific 
binding.  Subsequently, the serum was drained from the slides, and they were 
placed in a humidity chamber.  The primary antibodies, anti-CMV IE and anti 
CMV-gB, were diluted 1:200 and 1:300, respectively, in 2% Horse serum in TBS 
(Antibody Dilution Solution, ADS).  These were added to all slides in the humidity 
chamber and incubated at 37oC for 30 minutes.  The excess antibody was then 
removed, and the slides were rinsed in TBS.  Subsequently, the secondary 
antibody, Biotinylated Horse Anti-Mouse IgG (BHAM) (Vector Laboratories, 
Burlingame, CA) was placed on the slides at a dilution of 1:200 in ADS.  Slides 
were incubated at 37oC for 10 minutes and rinsed with TBS three times.  Next, 
Horseradish Peroxidase Avidin D (HP) (Vector Laboratories) was applied to the 
slides at a dilution of 1:500 in ADS, and slides were incubated at 37oC for 10 
minutes. Meanwhile, AEC substrate solution was prepared by addition of one 
tablet AEC to 2.5 mL N,N-Dimethylformamide and dilution in 47.5 mL acetate 
buffer and 25 uL H2O2 (30%).  Following incubation, slides were rinsed three 
times in TBS and incubated in acetate buffer 5 minutes.  All slides were 
developed in AEC substrate solution, and the reaction was stopped with acetate 
buffer.  Slides were then coverslipped with glycerin jelly (AFIP formula, OSU 
Stores) and examined microscopically. 
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Generation of glioblastoma cell lines constitutively expressing luciferase.  
To generate a GBM cell line that could be used in an in vivo model of human 
PCNS tumor, the Gli3605 cell line was transfected with the pGL3-Luc (or control 
pGL3) plasmid vector.  pGL3 is a circular plasmid that constitutively drives 
expression of firefly luciferase and the neomycin resistance gene.  To determine 
a toxic dose of neomycin, Gli3605 cells were plated in the presence of increasing 
concentrations of G418 (neomycin from GibcoTM Inc).  After one week, we found 
that 95% of Gli3605 cells had died (by trypan blue dye exclusion) when plated in 
presence of 1.5 mg/ml G418.  When assessed at 2 weeks, 100% of Gli3605 cells 
had died (compared to 90% of cells plated at 1.25 mg/ml).  Therefore, we chose 
this concentration as the condition to select positive transfectants.  We utilized 
the Lipofectamine 2000 reagent (InvitrogenTM Inc.) to transfect pGL3-Luc and 
control vector into Gli3605 cells following manufacturer’s recommendations. Cells 
were expanded for 48 hours after transfection to allow for adequate neo 
resistance gene expression and then placed into selection media containing 1.5 
mg/ml of G418.  After expanding in selection media for 3 weeks, pGL3-Luc and 
pGL3 polyclonal populations demonstrated 100% viability (compared to 0% 
viability of control Gli3605).  We then subcloned G418 resistant cells (1 cell / 
well) into 96 well plates and allowed clones to expand.  30 single clones were 
isolated and checked for luciferase expression.  The five brightest clones were 
then expanded and tested in the presence of luciferin for fluorescence intensity in 
vitro and in vivo utilizing the IVIS system.    
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RESULTS 
Depsipeptide and HDACi 42 can induce apoptosis in human glioblastoma 
and neuroblastoma cell lines.   To investigate the effects of the two histone 
deacetylase inhibitors on each of the four cell lines, a dose titration was 
performed.  For each cell line, 250,000 cells were plated per condition.  
Depsipeptide (DP) was added at concentrations of 0, 10, 50, 100, and 500 nM 
and washed out after 4 hours; HDACi 42 was used at concentrations of 0, 1, 2, 3, 
and 5 uM and either washed out after 4 hours or left in for duration of the 
experiment.  DMSO was used as the vehicle control.  At 24 and 48 hours, cells 
were harvested and stained with either propidium iodide or annexin V/topro III 
and analyzed by flow cytometry.  In the glioma lines, U251 and Gli3605, and the 
neuroblastoma lines, NB11 and NB 11 CMV, treatment with DP and HDACi 42 
resulted in dose-dependent induction of apoptosis (Figure 2).  In DP 500nM, 
apoptosis percentages were as follows:  NB11 CMV-27.7%, NB11-14.5%, 
Gli3605-76.9%, and U251-43.3%.  When 5uM HDACi 42 was used, percentages 
were:  NB11 CMV-51.8%, NB11-68.5%, Gli3605-21.5%, and U251-40.5%.  
Changes in cellular morphology consistent with programmed cell death were also 
documented in NB11 and NB11 CMV lines (Figures 3 and 4).  For both DP and 
HDACi 42, large, detached floating foci of cells were seen, and the amount of foci 
visibly increased with drug dose concentration.  
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Depsipeptide induces cell cycle arrest in Gli3605 at 24 hours.  In addition to 
the apoptotic capabilities of DP, another dose titration showed that the drug 
induced cell cycle arrest in GBM cell lines.  Concentrations of 0, 10, 50, 100, and 
500 nM DP were tested, and a cell cycle analysis was performed at 24 and 48 
hours using PI (propidium iodide) buffer, Becton-Dickinson’s FACscalibur flow 
cytometer, and CellQuest software.  The results demonstrate 47-58% of cells 
arrested in G2/M at 24 hours, followed by an exit from arrest and an average of 
49% apoptosis at 48 hours (Figure 5).     
 
Histone deacetylase 1 and 2 protein expression is increased in human 
brain tumors.  We consistently observed notable variation amongst different cell 
lines in susceptibility to HDACi-induced apoptosis.  One potential mechanism 
contributing towards resistance to the proapoptotic effects of HDACi may involve 
upregulation of HDAC enzymes.  Western blot and Ponceau staining procedures 
targeting HDAC1 and 2 were performed on twelve patient brain tumor samples 
by the lab of Dr. Antonio Chiocca in the Department of Neurological Surgery at 
OSU College of Medicine and Public Health.  These results show the elevated 
expression of HDAC1 and HDAC2 proteins in some GBM tumors (Figure 6).  In 
data not shown, the levels of HDAC1 and 2 proteins directly correlated with 
HDAC activity (personal communication E.A. Chiocca).   
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CMV alters cellular morphology.  NB11 and NB11 CMV were useful as CMV 
positive and negative cancer lines to evaluate the consequences of HDACi in 
CMV + cancer (Figure 7).  The morphology of NB11 cells shows spindle-like cells 
with dendritic-like projections, and they tend to aggregate into foci.  The NB11 
CMV cells, however, are larger, with fewer projections, absence of cellular 
aggregation and grow as a monolayer.  NB11 CMV cells appear to form syncytia, 
and inclusion bodies are also evident, which are likely secondary to CMV 
pathogenic effect on the line.  Both of these cell lines were stained with IE and 
gB antibodies using immunohistochemical staining techniques (data not shown).  
The staining confirmed that the CMV negative nature of NB11 cells while the 
NB11 CMV cells were 50% positive for infection.  The third cell line employed for 
use with CMV was the fibroblast line MRC5 (Figure 8).  This cell line was infected 
with CMV (strain AD169) for the purpose of isolating RNA to clone the UL97 
gene product.  It is apparent that the uninfected fibroblasts have a long, flat, 
spindle-like shape, while the infected cells draw in their extensions and develop a 
more rounded appearance.   
 
Cloning of UL97.  Following RNA isolation from the MRC5 fibroblasts, a reverse 
transcription was performed to obtain cDNA.  The primers specific for UL97, 5’ 
(UP) EcoRI-CCGGAATTCCATGTCCTCCGCACTTC GGTCTCG-3’ and 5’ (DN) 
Xho-GGCCTCGAGTTACTCGGGGAACAGT TGGCGGCA-3’, were then utilized 
in PCR (Figure 9).  The resulting 2.1 kB products were purified and ligated into 
the TOPOR vector, which was checked for correct size with insert by lysing with 
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phenochloroform and running on a 1% agarose gel with Supercoil DNA marker 
(Figure 10).  Finally, a mini prep was performed using the Eppendorf Fast 
Plasmid MiniTM protocol (Figure 11).  This verified the proper insert and vector 
sizes of 2.1 kB and 3.9 kB, respectively. Four clones of the correct sizes were 
selected for sequencing, and all were verified to be 97-98% homologous to the 
UL97 protein kinase (Figure 12).  Once isolated, the UL97 gene was cloned into 
the bacterial expression vector pGEX (Not1 and EcoR1 sites) for expression and 
isolation of large amounts of UL97 to evaluate phosphorylation assays using 
novel nucleoside analogues synthesized in collaboration with Dr. Werner Tjarks 
from the OSU College of Pharmacy (not shown). 
   
The UL97 gene product is induced by HDACi.  We have previously 
demonstrated that expression of viral kinase proteins in CNS tumors from 
patients with Epstein-Barr virus positive tumors presents an attractive opportunity 
to deliver selective, anti-tumor activity (66 and figure 15).  Basal levels of the 
protein kinase UL97 transcript were found to be difficult to amplify with one round 
of PCR suggesting that this gene product is not commonly expressed in CMV+ 
tumor lines.  Our lab has previously demonstrated that several EBV gene 
products are induced following treatment with hypomethylating agents and 
HDACi supporting the notion that herpesvirus gene expression is tightly 
regulated and subject to transcriptional silencing.  We therefore utilized HDACi in 
an attempt to induce the expression of the UL97 protein with the intent to confer 
sensitivity to the antiviral drug ganciclovir.  NB11 and NB11 CMV cells were 
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plated in the presence of media containing DP and HDACi 42.  DP was used in 
concentrations of 0, 10, 50, and 100 nM and washed out after a 4 hour 
incubation; HDACi 42 was used in concentrations of 0,1, 5, and 10 uM and 
remained in the media.  At 48 hours, the cells were harvested, and RNA was 
isolated for each condition.  A reverse transcription was performed on all 
samples, and the resulting cDNA was amplified by PCR to determine the levels 
of UL97 and 18S transcript present for each condition (Figures 13 and 14).  PCR 
was performed on 2.5 uL cDNA and cDNA diluted 1:10 (for semiquantitative 
analysis), and the products were loaded on a 1% agarose gel for evaluation of 
relative amounts of amplified products.  For NB11 CMV, the levels of UL97 
increased relative to the 18S band intensity as doses of each drug increased.  
For NB11, there was no detectable UL97 amplified.   Real time quantitative PCR 
studies are presently underway to verify our findings.   
 
Depsipeptide enhances NB11 CMV sensitivity to Ganciclovir in vitro.  To 
determine if enhanced expression of the UL97 gene product was associated with 
enhanced sensitivity to the antiviral drug GCV, we performed a series of 
experiments evaluating combination HDACi / GCV therapy in NB11 and NB11 
CMV cells.  Cell lines were plated in 0, 50, and 100nM DP, which was washed 
out after a 4 hour incubation.  Half of the samples were then treated with 
100ug/mL GCV and allowed to incubate for 24, 48 and 72 hours.  At 24, 48 and 
72 hours, cells were harvested, stained with Annexin V/Topro III and analyzed for 
apoptosis on Becton-Dickinson’s FACscalibur flow cytometer using CellQuest 
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software.  The results showed enhanced sensitivity to GCV for NB 11 CMV 
(Figure 16 and 17).  While the sensitivity of NB11 was also enhanced, the same 
level of synergy was not achieved.  Depsipeptide acts by increasing transcription 
of the UL97 protein kinase, which may then phosphorylate the antiviral GCV 
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DISCUSSION 
  While modern advances in surgery, radiotherapy and targeted therapy have 
led to enhanced survival in multiple solid and hematologic malignancies, 
conventional and experimental therapies for primary CNS tumors have not 
improved.  Thus, it is necessary to explore novel therapeutic approaches that 
address new targets and newly discovered regulatory mechanisms that 
contribute to cellular transformation.  The field of epigenetics has identified 
several mechanisms that contribute to tumor suppressor gene silencing.  Thus, 
drugs that interfere with epigenetic processes have become attractive candidates 
to test in preclinical and clinical trials.  In addition, HDACi and hypomethylating 
agents have recently been shown to contribute to covalent modification of 
histone proteins and DNA in several large herpesvirus genomes such as EBV 
and CMV.  Drugs that target these epigenetic processes have been shown to 
promote gene expression of viral gene products that are normally tightly 
regulated or silenced.  The association tying CMV infection with the most 
common primary CNS tumor, GBM, therefore presents an attractive opportunity 
to utilize the virus as a tool to aid in enhancing tumor-specific therapy.   
Gliomas are accountable for 77% of all malignant brain tumors, 51.9% of 
which are glioblastomas (5). Currently, the standard treatments for brain tumors 
include surgery, radiation therapy, and chemotherapy, which may be used either 
individually or in combination.  These treatments present problems because of 
their toxicity, lack of effectiveness, and lack of precise targets which would allow 
- 25 - 
for tumor-specific therapy.  Because the average survival rates of patients with 
GBM is projected at only a little over a year, and five-year survival rates are less 
than 5%, the results of this paper could indicate the beginning of a novel tumor 
therapy strategy (1, 4, 7).    
   A majority (about 90%) of malignant gliomas are infected by HCMV, and 
multiple HCMV gene products are presented in these tumors (27).  This gives 
justification to the strategy of using HDACi, which act to derepress viral gene 
promoters that are normally silenced secondary to tight histone-induced 
chromatin condensation. The amino tails of histone proteins are deacetylated by 
corepressor proteins like HDAC1 and 2 leading to “tight” chromatin structure.  
Drugs that inhibit HDAC activity allow for HAT protein activity to predominate 
resulting in acetylation of histones and “loose” chromatin structure.  This 
promotes multimeric protein complexes (SWI/SNF) that remodel chromatin to 
access promoter regions, allowing for transcription factor association and gene 
expression.  Currently, depsipeptide has been shown in various studies to have 
cytotoxic, antiproliferative activity against at least 12 human cancer cell lines both 
in vivo and in vitro (62, 64).  Preliminary in vitro and in vivo studies have also 
shown that HDACi 42 has potent antitumor activity in a variety of cancers (61).  
Drugs with HDACi activity are attractive candidates for CMV+ GBM given the 
associated antitumor activity and the ability to enhance expression of viral gene 
products that can be targeted.  Because the CMV protein kinase UL97 appears 
to be “silenced” in most models and is capable of phosphorylating GCV, we 
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hypothesized that HDACi would contribute to UL97 transcriptional activation, 
thereby providing a viral protein to target with nucleoside analogues.   
  Cytomegalovirus-infected brain tumor cells that are exposed to depsipeptide 
or HDAC-42 are sensitized to the antiviral ganciclovir, which adds to the 
antitumor effect of HDACi.  We show here that HDACi leads to enhanced UL97 
transcription that is associated with this enhanced antitumor effect. 
Cytomegalovirus is responsible for changes in morphology and, perhaps, plays a 
role in oncogenesis through cellular transformation and immortalization (16-26).  
It also clear that HDACi alone facilitate apoptosis and cell cycle arrest in both 
glioma and neuroblastoma lines.  Our preliminary studies show that the greatest 
amount of apoptotic activity appears to be at 48 hours after treatment, and G2/M 
cell cycle arrest appears at 24 hours.  While this project is early in its 
development, our findings may have implications that apply to both oncology and 
infectious disease problems.  CMV is a ubiquitous infectious agent associated 
with a wide variety of pathology.  It will be interesting to test whether HDACi 
alone or in combination with other epigenetic agents (5-Aza, Decitabine) lead to 
more impressive expression of the UL97 gene product conferring greater 
sensitivity to GCV.    
 We are presently working towards clarifying the mechanism by which 
HDACi leads to UL97 expression.  We are also utilizing SiRNA and antisense 
RNA experiments to “knock out” UL97 expression to see if this protein is vital to 
the enhanced antitumor effect of HDACi + GCV.  In addition, we are collaborating 
with Dr. Werner Tjarks (OSU Pharmacy) to test novel nucleoside analogues with 
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recombinant UL97 synthesized in our lab.  We are extending the findings from 
our neuroblastoma CMV+ model to a CMV+ GBM model.  We are about to begin 
generating CMV+ Gli3605 and U251 glioma lines to perform experiments 
examining the effects of HDACi on cell death, UL97 gene activation, and 
combination HDACi and GCV therapy treatment.  The epigenetic regulation of 
UL97 and prosurvival mechanisms that are activated following HDACi treatment 
will also be examined.  Finally, we have developed an in vivo model of GBM 
using Gli3605 cells that have been engineered to constitutively express 
luciferase (Figure 18).  This preclinical model will allow us to use the in vivo 
imaging system to monitor CNS tumor burden in real time during our therapeutic 
trials.  If this trial proves successful, a phase one trial in patients with CMV+ GBM 
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Figure 1:  HAT v. HDAC activity.  In the cell, histone 
acetyltransferases (HATs) promote relaxation of nucleosomal 
structures, allowing transcription to occur, while histone 
deacetylases (HDACs) promote chromatin compaction for 
transcriptional repression
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Figure 2:  Dose-dependent HDACi induction of cell death 
at 48 hours.  In (A), 0, 10, 50, 100, and 500 nM concentrations 
of depsipeptide were added and washed out after four hours.  
In (B), 0, 1, 2, 3, and 5 uM levels of HDACi 42 were added and 
left in.  Both HDACi induced apoptosis. 
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Figure 3:  Morphology of depsipeptide treatment in NB11 and NB11 CMV.  
Adhered cells were incubated in drug for 4 hours, washed with PBS, and fresh 
growth media was added.  Cells were viewed at 24 and 48 hours for 
morphological change.  NB11 CMV cells appeared largely unaffected at 48hr 
compared to the parent line NB11 which demonstrated loss of adherence, 

















Figure 4:  Morphology of HDACi 42 treatment in NB11 and NB11 CMV.  
Adhered cells were incubated in drug continuously.  Cells were viewed at 24 and 
48 hours for morphological change.  Similar to results obtained with 
depsipeptide, NB11 CMV cells appeared largely unaffected at 48hr compared to 
the parent line NB11, which demonstrated loss of adherence, cellular clumping 
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Figure 5:  Depsipeptide induction of cell arrest and 
apoptosis in Gli3605. At 24 hours, induction of cell cycle 
arrest was seen in G2/M at all doses.  By 48 hours, an 
average of 49% of the cells had become apoptotic for each 
concentration of 10, 50, 100, and 500 nM.    
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Figure 6:  HDAC1 and HDAC2 protein expression in 
human brain tumors.  Both proteins were increasingly 
expressed in tumor cells, as shown by Western Blot and 
Ponceau staining.  Samples obtained from twelve patients, 
with three from patient VI analyzed (courtesy of Dr. Ennio 
Chiocca, Department of Neurological Surgery, OSU College 
of Medicine and Public Health). 




Figure 7:  Morphology of NB11 and NB11 CMV cells.  The NB11 line 
demonstrates loss of contact inhibition, growing in foci, and spindle-like 
morphology, while the CMV+ converted NB11 line shows larger size, lack of foci, 
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Figure 8:  CMV alteration of fibroblast morphology.
Normal f ibroblasts retain a long, f lat, spindle-like 
shape (A).  CMV causes f ibroblasts to draw in their 
cellular extensions and develop a more rounded, 
raised morphology (B).
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Figure 9:  PCR replication of the UL97 gene product.  
CMV cDNA was isolated from AD169 infected f ibroblasts, and 
UL97 w as amplif ied.  The 2.1 kB products are visible in lanes 
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Figure 10: Determination of vectors containing insert.  
Samples of  colonies grow ing in TB+Amp tubes were lysed w ith 
phenochloroform.  The resulting aqueous layer was loaded on a 
1% agarose gel w ith Supercoil DNA marker.  All colonies were 









Figure 11:  Mini prep for determination of correct insert 
size.  Eight samples w ere mini prepped and subsequently 
digested w ith EcoRI to verify 2.1 kB size of the UL97 insert and
3.9 kB TOPOR vector size.  Seven colonies were conf irmed, 
and four were selected for sequencing.  
 




































Figure 12: Sequencing of vector inserts.  Clones w ith inserts 
of  the correct size were sent for sequencing using M13 forward 
and reverse primers w ith T3 and T7 polymerases, and all clones 
returned 97-98% homology to the UL97 CMV protein kinase, as 
determined using NCBI Nucleotide Blast software. 
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Figure 13: Depsipeptide induction of UL97 and 18S in 
NB11-CMV.  At concentrations of 10, 50, and 100 nM, DP 
induced expression of the UL97 CMV and the cellular 18S 
proteins at 48 hours.  In the CMV- line, NB11, no expression of 
UL97 w as induced.  Undiluted and 1:10 dilutions of  cDNA were 
used for each PCR reaction, and samples were loaded on a 
1% agarose gel.  
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Figure 14:  HDACi 42 induction of UL97 and 18S in NB11 
CMV. At concentrations of 1, 5, and 10 uM, HDACi 42 
induced expression of  the UL97 CMV and the cellular 18S 
proteins at 48 hours.  In the CMV- line, NB11, no expression 
of UL97 was induced.  Undiluted and 1:10 dilutions of cDNA 
were used for each PCR reaction, and products were loaded 
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Figure 15:  PCNSL and consequences of EBV thymidine kinase expression.  
Primary CNS lymphoma in a patient with EBV+ lymphoproliferative disease.  (A) 
Multiple tumor foci throughout the brain parenchyma were found on diagnosis. (B) 
Stereotactic core biopsy was performed showing EBV antigens and in-situ RT-PCR 
demonstrated the presence of the EBV ORF BXLF1, a viral thymidine kinase 
capable of phosphorylating the nucleoside analogue AZT. Left panel is a positive 
control (B95.8 cells), mid panel is negative control (EBV- osteosarcoma cell line), 
and right panel is the biopsy demonstrating multiple positive signals indicating 
abundant expression of the vTK gene product. (C) Following 2 wks of high dose 
AZT/GCV, this patient attained a complete response and is now cured of his 
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Figure 16: Ganciclovir addition increases apoptosis.  
Addition of 100 ug/ml GCV resulted in increased 
apoptosis at 48 hours (A) and 72 hours (B) compared to 
depsipeptide alone.  Between NB11 and NB11 CMV, 
















Figure 17: Ganciclovir addition increases apoptosis (expt
2).  NBII CMV+ cells demonstrate enhanced apoptosis by 
Ann/ToproIII FACS assay.  Cells were treated w ith DP (50nM) 
for 4 hours, washed, and subsequently placed in absence or 
presence of GCV (100ug/ml).  CMV+ cells that demonstrated 
increased UL97 transcript follow ing treatment w ith HDAC-I w ere 
more susceptible to GCV-induced cell death. Top panel NBII and 
bottom panel is NBII CMV 
 










Figure 18:  Gli3605 tumor cells expressing luciferin in 
animal model.  Gli3605 cells constitutively expressing the 
luciferin gene were injected into the thigh of the animal 
model and allowed to proliferate.  These tumors will be 
targeted with depsipeptide and HDACi 42. 
 
 
